Background
Broadly neutralizing antibodies (bNAbs) are promising HIV-1 immunoprophylactics, conferring protection in both preclinical and clinical studies. To overcome viral resistance to individual antibodies, bispecific bNAbs have been generated to increase breadth. We previously established that the bispecific 10E8.4/iMab, which targets the membrane-proximal external region of HIV envelope and the CD4 receptor, protects against high-dose intravenous SHIV-BG505 challenge. However, the importance of the timing of antibody administration relative to viral exposure remains unknown.
Methods
Indian-origin rhesus macaques (n=25) were divided into five groups (n=5) and challenged intravenously with high-dose SHIV-BG505 (40 × 10⁶ viral RNA copies). Experimental groups received 10E8.4/iMab (30 mg/kg) one hour before, simultaneous with, or one or 24 hours after viral exposure. The control animals received saline. All animals were monitored weekly for the development of viremia. ELISAs were used to monitor plasma antibody concentrations. To assess for subclinical infections, all animals that were aviremic at week eight post-challenge underwent CD8 depletion.
Results
The SHIV-BG505 virus is sensitive to 10E8.4/iMab neutralization (IC50 <0.01 ug/ml). All control animals rapidly developed viremia following high-dose intravenous SHIV-BG505 challenge. In contrast, no viral replication was detected in animals that received 10E8.4/iMab one hour before or at the time of exposure, even after five weeks post-CD8 depletion. Among animals administered 10E8.4/iMab one or 24 hours after exposure, 9 of 10 exhibited viral replication, becoming viremic once bioavailable antibody was no longer detectable or following experimental CD8 depletion.
Conclusions
The 10E8.4/iMab bispecific shows strong potential as an HIV-1 immunoprophylactic, with optimal protection achieved when administered at or before the time of viral exposure. The limited efficacy observed with post-exposure dosing suggests that at least a portion of the inoculum has completed viral entry within one hour of inoculation. Notably, the development of anti-drug antibodies and the rapid clearance of 10E8.4/iMab in macaques could result in an underestimation of the potential effectiveness of delayed administration in humans.